Home Diseases and Conditions Prostate Cancer 

Prostate Cancer 

Last Updated:
Development Stage

Early Stage

Focused ultrasound research is in the laboratory phase and is not yet available for patients.

Clinical Trials

Focused ultrasound for this condition is being researched in clinical trials.

International Approval

Focused ultrasound is approved to treat this condition outside the US. Patients can seek commercial treatment at participating international sites.

FDA Approved

The US Food and Drug Administration has approved focus ultrasound for this condition. Patients can seek commercial treatment at participating sites.

Early Stage

Clinical Trials

International

FDA Approved

Focused ultrasound is cleared to treat this condition both within and outside the US. Patients can seek commercial treatment at participating sites. There are also clinical trials that may be of interest to patients.

Focused Ultrasound Therapy

Focused ultrasound is a noninvasive, radiation-free method to destroy prostate tissue and treat prostate disease. Using real-time image guidance, the physician directs a focused beam of ultrasound energy to a selected volume in the patient’s prostate gland.

How it Works
Focused ultrasound energy heats and destroys the targeted tissue at the focal point within seconds. This process is repeated until the entire selected volume or the entire gland is destroyed.

Advantages
The primary options for treatment of prostate cancer include the avoidance of invasive procedures that may include ionizing radiation and surgery.

Focused ultrasound is a low-morbidity treatment that usually only requires a single therapy session and has a short recovery time. It is reported to have a low complication rate, especially when considering post-procedure impotence and incontinence. Focused ultrasound treatment does not use ionizing radiation, and it is possible to offer it as a salvage therapy for patients who fail radiation treatment. Focused ultrasound treatment can be a complement to drug therapy, enabling enhanced delivery of chemotherapy or immunotherapy to tumors, and it may potentially induce an anti-tumor immune response.

Clinical Trials

The PRISM clinical trial in New York is investigating the rates of recurrence after HIFU treatment.  

A second clinical trial in New York is evaluating clinical outcome for patients that have had HIFU treatment. 

A clinical trial in Florida is looking at patients quality of life outcomes, with localized radiorecurrent prostate cancer when treated with a the Focal One device.

A clinical trial in California is comparing treatment of prostate cancer with thermal ablation or with cryotherapy.  

A clinical trial in Southern California is comparing the outcomes for different focal therapy devices for treatment of prostate cancer.   

A registry for the TULSA-PRO is tracking patient outcomes for this device.

A multi-site clinical trial in the US, Canada and Finland is completing a randomized trial comparing the TULSA PRO to radical prostatectomy.   

A clinical trial in Ohio is comparing a single port robotic, partial prostatectomy to focused ultrasound in patients with prostate cancer.  

A clinical trial in Southern California is evaluating quality of life questionnaires for patients that have had Sonablate treatments for prostate cancer.  

A clinical trial in Bethesda, Maryland is evaluating patients who are having the Tulsa-Pro treatment for low volume and low grade prostate cancer.  

A clinical trial in Minnesota is evaluating the use of the Tulsa-Pro for intermediate level patients who have prostate cancer.  

A clinical trial in London, UK is doing a long term study of patients treated with the Sonablate system for prostate cancer.  

A clinical trial in France is evaluating different methods of target analysis for treatment of patients with prostate cancer.  

A clinical trial in the Netherlands is evaluating the focal therapy for patients with prostate cancer.  

A clinical trial in Norway is comparing HIFU to active surveillance. 

A clinical trial in China is substitution focused ultrasound for one of the chemotherapies in patients with metastatic prostate cancer.  

A clinical trial in China is comparing the quality of life outcomes from patient who had the Sonablate HIFU system to those that have had prostatectomy.  

A clinical trial in Singapore is evaluating a variety of focal therapies, including focused ultrasound, for the use in patients with prostate cancer.  

A clinical trial in France is organizing, and will look at the quality of life outcomes from patients who have had either total prostatectomy of focal therapy for prostate cancer.  

A clinical trial, the Jupiter Registry, is organizing in Europe for looking at 5 year outcomes after patients have had focal therapy for prostate cancer.  

The Foundation updates these pages regularly, but with the increasing number of clinical trials, we want to be sure that our audience has the latest information available. Therefore, we also added the website search information for the above trials. If you click here, it will take you to the latest information available from https://www.clinicaltrials.gov/.

See a list of treatment sites >
See a list of laboratory research sites >

Find a Treatment Site

Search for a treatment center or clinical trial near you.

Regulatory Approval and Reimbursement

Focused ultrasound devices have been cleared to treat the prostate in approximately 50 countries, including the United States. Several systems for focused ultrasound ablation of prostate tissue are available in various geographical regions, each differing in their guidance method (ultrasound vs. magnetic resonance imaging) and approach – transrectal or transurethral.

While the Foundation attempts to keep the list of sites complete, there have been many purchases of the focused ultrasound systems. For the latest information on availability, we recommend contacting the manufacturers’ directly or using their online search functions. 

There are four focused ultrasound manufacturers that are approved in the US for the ablation (destruction) of prostate tissue – Sonablate Corp.,  EDAP-TMS, Profound Medical, and Insightec. Sonablate and EDAP deliver care outside of the MRI facility, so they are found in surgery centers and surgical suites, as well as in hospitals. 

There are additional sites that use mobile focused ultrasound equipment. These sites may not be listed on the EDAP, Sonablate, or Profound Medical sites, and the best way to find them is to contact local urologists to see if they have focused ultrasound capability.

Reimbursement for primary treatment in the US has been lagging, and Medicare and most insurance companies are either covering a portion of the expense or not covering it at all. In the specific instance of salvage therapy after failed radiation, some Medicare providers and commercial insurance carriers are covering focused ultrasound use in this setting. As always, it is best to check with your specific carrier.

Notable Papers 

Suggested Reading: Focused Ultrasound for Prostate Cancer Case Study (2021)

Bitton RR, Vertosick E, Khandwala Y, Korol G, Vickers A, Ehdaie B, Sonn G, Ghanouni P. Optimizing prostate cancer treatment with MR-guided focused ultrasound: the role of expanded ablation-to-lesion volume ratio. Eur Radiol. 2026 Jan 16. doi: 10.1007/s00330-025-12217-5. PMID: 41540208 

Roldan-Testillano R, Rodriguez-Sanchez L, Rodríguez Socarrás ME, de Andrés Boville G, Durazo-Ruiz F, Gómez Rivas J, Alfambra Fernández H, Sánchez Macías J, Bianco FJ, Miñana López B, Sanchez-Salas R. The role of focal therapy for localized prostate cancer: From diagnosis to ablation. Actas Urol Esp (Engl Ed). 2026 Jan 5:501918. doi: 10.1016/j.acuroe.2026.501918. PMID: 41500454 

Dokania S, Aphale P, Shekhar H. Optimizing Transurethral Ultrasound Ablation for Localized Prostate Cancer: Lessons from Functional and Imaging Outcomes. J Vasc Interv Radiol. 2026 Jan;37(1):107890. doi: 10.1016/j.jvir.2025.10.021. Epub 2025 Oct 28. PMID: 41167300 

Tricard T, Cazzato RL. Comments on Optimizing Transurethral Ultrasound Ablation for Localized Prostate Cancer: Lessons from Functional and Imaging Outcomes. J Vasc Interv Radiol. 2026 Jan;37(1):107894. doi: 10.1016/j.jvir.2025.10.025. Epub 2025 Oct 27. PMID: 41161408 

Li H, Cai Z, He P, Wu Y, Lu L, Gao Y, Sun L, Huang L, Dong X, Liu Z. Mechanical destruction of canine prostate using a novel low-intensity histotripsy based on a perfluoropentane-filled sodium alginate scaffold. Int J Hyperthermia. 2025 Dec;42(1):2579893. doi: 10.1080/02656736.2025.2579893. Epub 2025 Oct 29. PMID: 41158084 

Maurer A, Muehlematter UJ, Sivakumar T, Mortezavi A, Heimer J, Kaufmann B, Beintner-Skawran S, Messerli M, Huellner MW, Eberli D, Burger IA. High-Intensity Focused Ultrasound in Prostate Cancer: Can PSMA PET Improve Focal Therapy Outcomes? J Nucl Med. 2025 Dec 4:jnumed.125.271318. doi: 10.2967/jnumed.125.271318. PMID: 41344858 

Collins K, Cheng L. Treatment-related changes in the prostate: past, present and future therapies. Histopathology. 2026 Jan;88(1):40-52. doi: 10.1111/his.15507. PMID: 41384710 

Koehler J, Lama D, Mendez M, Hsu WW, Oto A, Szmulewitz R, Sidana A. Phase II trial protocol of focal prostate ablation combined with androgen deprivation therapy for prostate cancer treatment. PLoS One. 2025 Dec 16;20(12):e0337828. doi: 10.1371/journal.pone.0337828. eCollection 2025. PMID: 41401176 

Mercier J, Bento L, Cassou-Mounat T, Prudhomme T, Lagarde S, Game X, Soulie M, Thoulouzan M, Bajeot AS, Roumiguie M. Post-HIFU surveillance of localized prostate cancer: role of PSMA-PET imaging versus the standard PSA-mpMRI protocol. World J Urol. 2025 Dec 27;44(1):68. doi: 10.1007/s00345-025-06163-6. PMID: 41454965 

Yee CH, Chiu PK, Liu AQ, Wong HF, Chan WHC, Lo KL, Chan CK, Chan R, Cho CC, Hung HY, Teoh JYC, Ng CF. Multimodality focal therapy for prostate cancer: outcome of the à la carte approach in clinical practice. Prostate Int. 2025 Dec;13(4):201-206. doi: 10.1016/j.prnil.2025.03.006. Epub 2025 Mar 24. PMID: 41472926 

Korn SM, Qian Z, Zurl H, Piccolini A, Pohl KK, Xiao B, Lipsitz S, Zhang J, Kibel AS, Hübner NA, Moore CM, Shariat SF, Trinh QD, Cole AP. Claims-Based Analysis of National Utilization Patterns and Regional Variability of Prostate Cancer Ablative Therapies: A Medicare Study. J Endourol. 2025 Nov 18. doi: 10.1177/08927790251388065. PMID: 41253389 

Noun J, Blachman-Braun R, Lee E, Pinto PA. Focal Therapies for Localized Prostate Cancer. Urol Clin North Am. 2026 Feb;53(1):115-134. doi: 10.1016/j.ucl.2025.09.010. Epub 2025 Nov 5. PMID: 41265994 

Torres J, Accary V, Payen T, Delattre V, Lafon C. Acoustic focal characteristics of a transrectal phased array under heterogeneity and weak nonlinearity. J Acoust Soc Am. 2025 Nov 1;158(5):4146-4158. doi: 10.1121/10.0039947. PMID: 41283708 

Ehrengut C, Alberalar ND, Franz T, Horn LC, Blana A, Hadaschik B, Stolzenburg JU, Schlemmer HP, Ebel S, Timm Denecke S, Ganzer R, Schaudinn A. Evaluation of the TARGET score for MRI-based detection of prostate cancer recurrence in patients treated with HIFU hemiablation. Eur J Radiol. 2025 Nov 24;195:112572. doi: 10.1016/j.ejrad.2025.112572. PMID: 41319370 

Ivey MC, Deivasigamani S, Kotamarti S, Mottaghi M, Ghoreifi A, Adams ES, Jhaveri H, Robertson CN, Kruse DE, Kalisz KR, Marin D, Thomas SP, Polascik TJ, Gupta RT. External validation of inter-reader reliability of the Prostate Imaging after Focal Ablation (PI-FAB) scoring system following focal cryoablation and focal high-intensity focused ultrasound. Eur Radiol. 2025 Nov;35(11):7004-7012. doi: 10.1007/s00330-025-11513-4. Epub 2025 Apr 2. PMID: 40172640 

Kaplan-Marans E, Edwards C, West M, Katlowitz YE, Vazquez-Rivera K, Schulman A, Silver D. Cryotherapy and High-Intensity Focused Ultrasound: National Utilization Trends (2016-2022). Urol Pract. 2025 Nov;12(6):648-651. doi: 10.1097/UPJ.0000000000000856. Epub 2025 Jul 8. PMID: 40536487 

Yeh HT, Liu YY, Chang YL, Liu HY, Shen YC, Wang HJ, Chen YT, Chuang YC, Luo HL. 10-year oncological outcomes of EBRT versus HIFU for stage II prostate cancer: a multicenter Chang Gung research database (CGRD) study with inverse-probability-of-treatment weighting (IPTW) analysis. Int Urol Nephrol. 2025 Oct 7. doi: 10.1007/s11255-025-04805-7. PMID: 41055797 

Khanal N, Marciniak MA, Daniel MC, Zhu L, Dumoulin C, Stringer K, Myers MR, Yarmolenko P, Banerjee RK. Assessing Fab-Functionalized Gold Nanoparticles-Mediated Thermal Enhancement during High-Intensity Focused Ultrasound Ablation in a Mouse Tumor Model. ACS Appl Bio Mater. 2025 Oct 13. doi: 10.1021/acsabm.5c00879. PMID: 41081487 

Ploussard G, Baboudjian M, Barret E, Brureau L, Dariane C, Fiard G, Fromont G, Mathieu R, Olivier J, Neuzillet Y, Rozet F, Peyrottes A, Renard-Penna R, Sargos P, Supiot S, Turpin L, Roubaud G, Rouprêt M. French recommendations from the AFU Cancer Committee for prostate cancer: 2025 summary of changes. Fr J Urol. 2025 Oct 16;35(12):103010. doi: 10.1016/j.fjurol.2025.103010. PMID: 41109641 

Eskandar K. FocalONE high-intensity focused ultrasound for localized prostate cancer: A systematic review of oncologic outcomes, functional preservation, and technological evolution. Actas Urol Esp (Engl Ed). 2025 Oct 22:501869. doi: 10.1016/j.acuroe.2025.501869. PMID: 41135772 

Johnson K, Mehan R. Removal of Prostate Calcifications Prior to TULSA-PRO With the Aid of Real-Time Ultrasound Imaging: Our Technique and Experience. Cureus. 2025 Sep 23;17(9):e92995. doi: 10.7759/cureus.92995. eCollection 2025 Sep. PMID: 40994761 

Chang M, Lv J, Sun L, Chen A, Zhang F, Fan G, Liu Z, Li J, Shen H, Shi M, Niu Y, Tian Y, Liu X, Yang B. Cu-Mn Bimetallic Mesoporous Silica Nanosonosensitizers Enable Oxeiptosis-Mediated Sonodynamic Therapy for Ultra-Minimally Invasive Treatment of Benign Prostatic Hyperplasia. ACS Appl Mater Interfaces. 2025 Sep 17;17(37):51820-51839. doi: 10.1021/acsami.5c12846. Epub 2025 Sep 5. PMID: 40911431 

Xiao B, Qian Z, Piccolini A, Dagnino F, Korn SM, Zurl H, Pohl KK, Stelzl DR, Moore CM, Wollin D, Trinh QD, Cole AP. Medicolegal landscape of prostate cancer ablative therapy: a national legal database analysis of malpractice claims (1970-2024). Int Urol Nephrol. 2025 Sep 9. doi: 10.1007/s11255-025-04766-x. PMID: 40926180 

Scherer TP, Lazos AG, Sonderer J, Kaufmann B, Schmid FA, Jenewein J, Rupp NJ, Moch H, Eberli D, Mortezavi A. Anxiety and Health-related Quality of Life in Men with Prostate Cancer Undergoing Focal Therapy: A Prospective Single-arm Phase 2 Trial. Eur Urol Focus. 2025 Sep 9:S2405-4569(25)00253-6. doi: 10.1016/j.euf.2025.08.006. PMID: 40930919 

Khanal N, Summey V, Bailey J, Duan X, Zheng Y, Zhu L, Stringer K, Rao M, Banerjee RK. Development of Mouse-Tumor Model Using Prostate Cancer (PC3) Cell Line for High-Intensity Focused Ultrasound (HIFU) Ablation. Prostate Cancer. 2025 Sep 6;2025:5678314. doi: 10.1155/proc/5678314. eCollection 2025. PMID: 40950564 

Cormio A, Castellani D. Editorial Comment on “Medium-Term Outcomes after Primary Whole-Gland High-Intensity Focused Ultrasound Ablation for the Treatment of Prostate Cancer: A Single-Center Experience”. J Endourol. 2025 Jul 3. doi: 10.1089/end.2025.0425. PMID: 40608541 

Wenzel M, Nathan A, Covas Moschovas M, Wagner C, Calleris G, Di Maida F, Gomez Rivas J, Bravi CA, De Groote R, Piramide F, Turri F, Kowalczyk K, Würnschimmel C, Sharma G, Andras I, Lambert E, Liakos N, Darlington D, Paciotti M, Sorce G, Mandel P, Galfano A, Nathan S, Marra G, Dell’Oglio P, Mottrie A, Chun FKH, Patel V, Breda A, Larcher A. Oncological Outcomes After Robotic Salvage Radical Prostatectomy in Patients Primarily Treated With Focal Versus Radiation Therapy: A Junior ERUS/YAU Collaborative Study. Prostate. 2025 Jul 23. doi: 10.1002/pros.70020. PMID: 40702693 

Lepine HL, Vicentini FC, Filho CM, Cavalcante G, Llata FM, Júnior JB, Reis LO, Mota JM, Nahas WC, Ribeiro-Filho LA, Suartz CV. Evaluating less-invasive strategies for localized prostate cancer: a comparative meta-analysis on high-intensity focused ultrasound versus radical prostatectomy. Int Urol Nephrol. 2025 Jul 31. doi: 10.1007/s11255-025-04695-9. PMID: 40742653 

Shee K, Pace WA, Liu AW, Cowan JE, Subramanyam V, Agapito C, Washington SL 3rd, Cooperberg MR, Carroll PR, Shinohara K, Nguyen HG. Determining Optimal Patient Selection for High-intensity Focused Ultrasound for Prostate Cancer. Eur Urol Focus. 2025 Aug 2:S2405-4569(25)00174-9. doi: 10.1016/j.euf.2025.06.007. PMID: 40754483 

Rosnitskiy PB, Thomas GPL, Lee GL, Khokhlova VA, Sapozhnikov OA, Schade GR, Morrison KP, Chavez F, Khokhlova TD. A Fully Populated Transrectal Array for Boiling Histotripsy Ablation of the Prostate. IEEE Trans Ultrason Ferroelectr Freq Control. 2025 Aug 7;PP. doi: 10.1109/TUFFC.2025.3596780. PMID: 40773382 

Kaneko M, Ramacciotti LS, Inoue Y, Peretsman S, Cummins J, Cai J, Halteh P, Palmer S, Aron M, Ukimura O, Gill IS, Abreu AL. Impact of magnetic resonance imaging visibility of prostate cancer on partial gland ablation. BJUI Compass. 2025 Aug 6;6(8):e70065. doi: 10.1002/bco2.70065. eCollection 2025 Aug. PMID: 40777065 

Katano A, Minamitani M, Sawayanagi S, Yamashita H. Salvage Radiation Therapy for Localised Prostate Cancer Recurrence Following High-Intensity Focused Ultrasound (HIFU) Failure. J Med Imaging Radiat Oncol. 2025 Aug 15. doi: 10.1111/1754-9485.70009. PMID: 40817649 

Artiles Medina A, Tagalos Muñoz A, Domínguez Gutiérrez A, Muriel García A, Subiela JD, Álvarez Díaz N, Fernández Conejo G, Gómez Dos Santos V, Coloma Del Peso A, Burgos Revilla FJ. Outcomes of Active Treatment for Localised Prostate Cancer After Holmium Laser Enucleation of the Prostate: A Systematic Review and Meta-analysis. Eur Urol Open Sci. 2025 Aug 11;79:111-127. doi: 10.1016/j.euros.2025.07.011. eCollection 2025 Sep. PMID: 40837058 

Pyrgidis N, Chaloupka M, Ebner B, Volz Y, Weinhold P, Marcon J, Eismann L, Stief CG, Schulz GB, Apfelbeck M. Perioperative complications of focal therapy for prostate cancer: results from the GeRmAn Nationwide inpatient Data (GRAND) study. BJU Int. 2025 Aug;136(2):306-313. doi: 10.1111/bju.16746. Epub 2025 Apr 19. PMID: 40251973 

Creta M, Shariat SF, Marra G, Gontero P, Rossanese M, Morra S, Teoh J, Kishan AU, Karnes RJ, Longo N. Local salvage therapies in patients with radio-recurrent prostate cancer following external beam radiotherapy: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2025 Sep;28(3):578-591. doi: 10.1038/s41391-024-00883-3. Epub 2024 Sep 2. PMID: 39223232 

Séguier D, Puech P, Barret E, Leroy X, Labreuche J, Penna RR, Ploussard G, Villers A, Olivier J. MRI accuracy for recurrence after partial gland ablation with HIFU for localized prostate cancer. A systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2025 Sep;28(3):592-600. doi: 10.1038/s41391-024-00885-1. Epub 2024 Sep 10. PMID: 39256551 

Shoji S, Naruse J, Ohno S, Aoki M, Takahashi K, Yuzuriha S, Kuroda S, Umemoto T, Nakajima N, Hasegawa M, Kawamura Y, Kajiwara H, Hashida K, Uemura K, Hasebe T, Tajiri T. Focal therapy using high-intensity focused ultrasound with intraoperative prostate compression for patients with localized prostate cancer: a multi-center prospective study with 7 year experience. Prostate Cancer Prostatic Dis. 2025 Sep;28(3):782-788. doi: 10.1038/s41391-024-00921-0. Epub 2024 Nov 23. PMID: 39580599 

Taratkin M, Androsov A, Morozov A, Azilgareeva C, Rivas JG, Puliatti S, Checcucci E, Belenchon IR, Kowalewski KF, Rodler S, Piazza P, Baekelandt L, Veccia A, De Backer P, Fajkovic H, Enikeev D, Cacciamani GE. Urinary Outcomes of Minimally Invasive Treatments for Prostate Cancer-A Systematic Review by Young Academic Urologists’ Urotechnology Working Group. J Endourol. 2025 Jun 10. doi: 10.1089/end.2024.0129. PMID: 40491395 

Piramide F, Veccia A, Tzelves L, Nikles S, Ortega Polledo LE, Nocera L, Khelif A, Dumbovic L, Lazarou L, Cisero E, Quarà A, Sterrantino A, Falagario U, Piazza P, Baekealndt L, Carrion DM, Gomez Rivas J, Cacciamani G, Checcucci E. Sexual function outcomes in men undergoing minimal invasive ablative techniques for prostate cancer: a ESRU/YAU urotech systematic review and pooled analysis. Minerva Urol Nephrol. 2025 Jun;77(3):285-297. doi: 10.23736/S2724-6051.25.06007-0. PMID: 40528769 

Shoji S, Takahashi K, Naruse J, Kawamura Y. Frontiers of Ultrasound Technology in Prostate Cancer Treatment. Int J Urol. 2025 Jun 22. doi: 10.1111/iju.70160. PMID: 40545780 

Sotoudehnia S, Leung BYC, Thompson SM, Adamo DA, Mynderse LA, Woodrum DA. Saline Displacement of Rectal Wall for Improved Margin During MRI-Guided Transurethral Ultrasound Ablation (TULSA). Cardiovasc Intervent Radiol. 2025 Jun 24. doi: 10.1007/s00270-025-04102-x. PMID: 40555770 

Bhattarai R, McKenney JK, Alaghehbandan R, Liu X, Cox RM, Myles JL, Przybycin CG, Williamson SR, Weight CJ, Schwen Z, Nguyen JK. Atypical Intraductal Proliferation in Prostate Needle Core Biopsy: Validation as a Marker of Unsampled Adverse Pathology in a Clinicopathologic Series of 142 New Patients. Am J Surg Pathol. 2025 May 1;49(5):515-522. doi: 10.1097/PAS.0000000000002376. Epub 2025 Feb 25. PMID: 39995242 

Rischmann P, Occéan BV, Ploussard G. Reply to Mario Terlizzi, Youssef Ghannam, and Pierre Blanchard’s Letter to the Editor re: Guillaume Ploussard, Patrick Coloby, Thierry Chevallier, et al. Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial. Eur Urol. 2025;87:526-533. Eur Urol. 2025 May;87(5):e92. doi: 10.1016/j.eururo.2025.02.018. Epub 2025 Mar 6. PMID: 40055030 

Brazão ÉS Jr, Oliveira RAR, Zanotti RR, Gomes DC, Mourão TC, Santos VE, da Silva C, Santana TBM, da Costa WH, Guimarães GC, Zequi SC. Medium-Term Outcomes after Primary Whole-Gland High-Intensity Focused Ultrasound Ablation for the Treatment of Prostate Cancer: A Single-Center Experience. J Endourol. 2025 May;39(5):500-508. doi: 10.1089/end.2024.0539. Epub 2025 Mar 26. PMID: 40135250 

Schröer S, Glandorf J, Düx D, Horstmann D, Gutt M, Belker O, Peters I, Hellms S, Wacker F, Hensen B, Gutberlet M. Improving necrosis estimation in MR-guided prostate focused ultrasound ablations with a probabilistic thermal dose model. Comput Biol Med. 2025 Jun;192(Pt B):110225. doi: 10.1016/j.compbiomed.2025.110225. Epub 2025 May 16. PMID: 40381478 

Viitala A, Anttinen M, Mäkelä P, Pärssinen H, Nurminen P, Sainio T, Saunavaara J, Taimen P, Sequeiros RB, Boström PJ. Magnetic resonance imaging-guided transurethral ultrasound ablation for benign prostatic obstruction: 1-year clinical outcomes of a phase II study. BJU Int. 2025 May 28. doi: 10.1111/bju.16795. PMID: 40432395 

Zhou H, Tang J, Wan Y, Gong J, Wang Q, Huang K, Hong R, Xu X, Li F. Platform-based BST-2-targeted microbubbles enhance HIFU therapy and effectively inhibit prostate cancer residual growth. Int J Hyperthermia. 2025 Dec;42(1):2511035. doi: 10.1080/02656736.2025.2511035. Epub 2025 May 28. PMID: 40436774 

Tricard T, Cazzato RL, Schroeder A, De Mathelin M, Barhoumi C, Gaillard V, Sauleau E, Gangi A, Lang H. Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation of Localized Prostate Cancer (MRI-TULSA): A Prospective Trial. J Vasc Interv Radiol. 2025 May 27:S1051-0443(25)00385-9. doi: 10.1016/j.jvir.2025.05.024. PMID: 40441432 

Viani GA, Hamamura AC. Re: Guillaume Ploussard, Patrick Coloby, Thierry Chevallier, et al. Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial. Eur Urol. In press. Eur Urol. 2025 May 30:S0302-2838(25)00204-0. doi: 10.1016/j.eururo.2025.02.032. PMID: 40450474 

Bertelli E, Vizzi M, Legato M, Nicoletti R, Paolucci S, Ruzga R, Giovannelli S, Sessa F, Serni S, Masieri L, Campi R, Neri E, Agostini S, Miele V. The Use of PI-FAB Score in Evaluating mpMRI After Focal Ablation of Prostate Cancer: Is It Reliable? Inter-Reader Agreement in a Tertiary Care Referral University Hospital. Cancers (Basel). 2025 Mar 20;17(6):1031. doi: 10.3390/cancers17061031. PMID: 40149364 

Ghai S, Ni TT, Pavlovich CP, Futterer JJ, Schade GR, Sanchez-Salas R, Cornud F, Eggener S, Feller JF, George AK, Villers A, de la Rosette J. New kids on the block: MRI guided transrectal focused US, TULSA, focal laser ablation, histotripsy – a comprehensive review. Prostate Cancer Prostatic Dis. 2025 Mar 27. doi: 10.1038/s41391-025-00956-x. PMID: 40140552 

Brazão ÉS Jr, Oliveira RAR, Zanotti RR, Gomes DC, Mourão TC, Santos VE, da Silva C, Santana TBM, da Costa WH, Guimarães GC, Zequi SC. Medium-Term Outcomes after Primary Whole-Gland High-Intensity Focused Ultrasound Ablation for the Treatment of Prostate Cancer: A Single-Center Experience. J Endourol. 2025 Mar 26. doi: 10.1089/end.2024.0539. PMID: 40135250 

Engelage L, Muschter R. Transurethral Ultrasound Ablation for Treatment of Localized Prostate Cancer and Benign Prostatic Hyperplasia (BPH). J Endourol. 2025 Mar;39(S1):S23-S26. doi: 10.1089/end.2024.0301. PMID: 40100835 

Ajami T, Williams A, Ryan JT, Prakash NS, Khandekar A, Sureshkumar K, Ritch CR, Gonzalgo ML, Punnen S, Parekh DJ, Nahar B. Use of biochemical and imaging criteria for selecting patients for prostate biopsy in recurrence risk assessment post-HIFU therapy. World J Urol. 2025 Mar 12;43(1):162. doi: 10.1007/s00345-025-05529-0. PMID: 40072595 

Pausch AM, Elsner C, Rupp NJ, Eberli D, Hötker AM. Comparative analysis of TARGET and PI-FAB scores in mpMRI surveillance after HIFU therapy for localized prostate cancer. Eur J Radiol. 2025 Mar 4;186:112028. doi: 10.1016/j.ejrad.2025.112028. PMID: 40058174 

Terlizzi M, Ghannam Y, Blanchard P. Re: Guillaume Ploussard, Patrick Coloby, Thierry Chevallier, et al. Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial. Eur Urol. In press. Eur Urol. 2025 Mar 4:S0302-2838(25)00121-6. doi: 10.1016/j.eururo.2025.01.027. PMID: 40044505 

Baude J, Teyssier C, Barbier V, Tremeaux JC, Azélie C, Lépinoy A, Henry PC, Bailly V, Lescut N, Lagneau E, Schipman B. Salvage radiotherapy with volumetric modulated arc therapy (VMAT) for recurrent prostate cancer after high-intensity focused ultrasound (HIFU): A large French retrospective series and literature review. Radiother Oncol. 2025 Feb;203:110665. doi: 10.1016/j.radonc.2024.110665. Epub 2024 Dec 15. PMID: 39681174 

Hedhli O, Marra G, Karam G, Glemain P, Chelghaf I, De Vergie S, Perrouin Verbe MA, Biancone L, Gontero P, Bouchot O, Rigaud J, Branchereau J. Prostate cancer in solid organ transplant recipients: Results from a multicenter series. Fr J Urol. 2025 Mar;35(2):102841. doi: 10.1016/j.fjurol.2024.102841. Epub 2024 Dec 4. PMID: 39643043 

Sidana A, Lazarovich A, Tayebi S, Huron A, Blank F, Tobler J, Verma S, Hsu WW. Prostate ablation for the management of localized prostate cancer. Urol Oncol. 2025 Mar;43(3):194.e9-194.e17. doi: 10.1016/j.urolonc.2024.11.009. Epub 2024 Nov 26. PMID: 39592359 

Kumar R, Ghai S, Finelli A, Klotz L, Kinnaird A, Mannas M, Bhindi B, Sanchez-Salas R, Anidjar M, Ahmad A, Chin J, Inman B, Perlis N. The use of focal therapy for the treatment of prostate cancer in Canada Where are we, how did we get here, and where are we going? Can Urol Assoc J. 2025 Feb;19(2):63-72. doi: 10.5489/cuaj.8888. PMID: 39418491 

Tamburini S, Bianchi L, Piazza P, Mottaran A, Ercolino A, Rotaru V, Pirelli V, Presutti M, Droghetti M, Schiavina R, Brunocilla E. Current role of focal therapy in prostate cancer. Urologia. 2025 Feb;92(1):67-74. doi: 10.1177/03915603241258713. Epub 2024 Nov 14. PMID: 39540262 

Rischmann P, Occéan BV, Ploussard G. Reply to Jason Koehler and Abhinav Sidana’s Letter to the Editor re: Guillaume Ploussard, Patrick Coloby, Thierry Chevallier, et al. Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.11.006. Eur Urol. 2025 Feb 6:S0302-2838(25)00062-4. doi: 10.1016/j.eururo.2025.01.022. PMID: 39920006 

Bochner E, Schulte V, Lotan Y, Meng X, Costa DN. Feasibility and Short-Term Safety of Hydrogel Spacer before Treatment with Magnetic Resonance Imaging-Guided Transurethral Ultrasound Ablation for Prostate Cancer Treatment. J Endourol. 2025 Feb 10. doi: 10.1089/end.2024.0700. PMID: 39925110 

Montorsi F, Gandaglia G, Stabile A. Re: Guillaume Ploussard, Patrick Coloby, Thierry Chevallier, et al. Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial. Eur Urol. In press. Eur Urol. 2025 Feb 15:S0302-2838(25)00063-6. doi: 10.1016/j.eururo.2025.01.023. PMID: 39956725 

Hsieh PF, Naruse J, Yuzuriha S, Umemoto T, Huang CP, Shoji S. Combining Percentage Prostate-Specific Antigen Reduction and Multiparametric Magnetic Resonance Imaging to Reduce Unnecessary Biopsy After Focal Therapy With High-Intensity Focused Ultrasound for Prostate Cancer. Int J Urol. 2025 Feb 19. doi: 10.1111/iju.70013. PMID: 39968685 

Matsuoka Y. Editorial Comment to “Combining Percentage Prostate-Specific Antigen Reduction and Multiparametric Magnetic Resonance Imaging to Reduce Unnecessary Biopsy After Focal Therapy With High-Intensity Focused Ultrasound for Prostate Cancer“. Int J Urol. 2025 Feb 27. doi: 10.1111/iju.70031. PMID: 40012537 

Muhler P, Akuamoa-Boateng D, Rosenbrock J, Stock S, Müller D, Heidenreich A, Simões Corrêa Galendi J. Cost-utility analysis of MR imaging-guided transurethral ultrasound ablation for the treatment of low- to intermediate-risk localised prostate cancer. BMJ Open. 2025 Jan 11;15(1):e088495. doi: 10.1136/bmjopen-2024-088495. PMID: 39800402 

Teoh JY, Wong CH. When precision meets prostate cancer: the rising role of HIFU focal therapy. Prostate Cancer Prostatic Dis. 2025 Jan 20. doi: 10.1038/s41391-025-00940-5. PMID: 39833291 

Su S, Wang Y, Lo EM, Tamukong P, Kim HL. High-intensity focused ultrasound ablation to increase tumor-specific lymphocytes in prostate cancer. Transl Oncol. 2025 Jan 24;53:102293. doi: 10.1016/j.tranon.2025.102293. PMID: 39862483 

Koehler J, Sidana A. Re: Guillaume Ploussard, Patrick Coloby, Thierry Chevallier, et al. Whole-gland or Subtotal High-intensity Focused Ultrasound Versus Radical Prostatectomy: The Prospective, Noninferiority, Nonrandomized HIFI Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2024.11.006. Eur Urol. 2025 Jan 24:S0302-2838(25)00021-1. doi: 10.1016/j.eururo.2024.12.021. PMID: 39863507 

Koehler J, Lazarovich A, Tayebi S, Viswanath V, George A, Hsu WW, Sidana A. Shifting tides: A survey analysis of urologists’ evolving attitudes toward focal therapy for prostate cancer. Indian J Urol. 2025;41(1):59-65. doi: 10.4103/iju.iju_239_24. Epub 2025 Jan 1. PMID: 39886635 

Click here for additional references from PubMed.

Video courtesy of SonaCare Medical